PLoS ONE (Jan 2022)

Gait alterations in Parkinson's disease at the stage of hemiparkinsonism-A longitudinal study.

  • Vladana Marković,
  • Iva Stanković,
  • Saša Radovanović,
  • Igor Petrović,
  • Milica Ječmenica Lukić,
  • Nataša Dragašević Mišković,
  • Marina Svetel,
  • Vladimir Kostić

DOI
https://doi.org/10.1371/journal.pone.0269886
Journal volume & issue
Vol. 17, no. 7
p. e0269886

Abstract

Read online

BackgroundProgressive gait impairment in Parkinson's disease (PD) leads to significant disability. Quantitative gait parameters analysis provides valuable information about fine gait alterations.ObjectivesTo analyse change of gait parameters in patients with early PD at the stage of hemiparkinsonism and after 1 year of follow up, taking into account clinical asymmetry.MethodsConsecutive early PD outpatients with strictly unilateral motor features underwent clinical and neuropsychological assessment at the study entry and after 1 year of follow up. Gait was assessed with GAITRite walkway using dual-task methodology. Spatiotemporal gait parameters (step time and length, swing time and double support time) and their coefficients of variation (CV), gait velocity and heel-to-heel base support were evaluated.ResultsWe included 42 PD patients with disease duration of 1.3 years (±1.13). Progression of motor and non-motor symptoms, without significant cognitive worsening, was observed after 1 year of follow up. Significant shortening of the swing time, prolongation of the double support and increase of their CVs were observed during all task conditions similarly for most parameters on symptomatic and asymptomatic bodysides, except for CV for the swing time under the combined task.ConclusionAlterations of the swing time and double support time are already present even at the asymptomatic body side, and progress similarly, or even at faster pace, at this side, despite dopaminergic treatment These parameters deserve further investigation in larger, prospective studies to address their potential to serve as markers of progression in interventional disease modifying trials with early PD patients.